Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420332 | 0.79 | PDE10A (0.60) | PDE10ANR1I2CYP3A4CYP2D6 | |
| SCHEMBL275864 | 0.79 | PDE10A (1.00) | PDE10ANR1I2CYP3A4CYP2D6 | |
| SCHEMBL1759464 | 0.79 | PDE10A (0.61) | PDE10ANR1I2CYP3A4CYP2D6 | |
| SCHEMBL4422007 | 0.77 | PDE10A (0.61) | PDE10A | |
| SCHEMBL719516 | 0.77 | TDP1 (0.47) | PDE10A | |
| SCHEMBL1706456 | 0.74 | PDE10A (0.54) | PDE10A | |
| SCHEMBL4430199 | 0.74 | PDE10A (0.48) | PDE10A | |
| SCHEMBL25393081 | 0.74 | PDE10A (0.54) | PDE10ANR1I2CYP3A4CYP2D6 | |
| SCHEMBL25390387 | 0.74 | PDE10A (0.54) | PDE10A | |
| SCHEMBL25391200 | 0.74 | PDE10A (0.54) | PDE10ANR1I2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | claimed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | claimed |
| WO-2018106641-A1 | PYRAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106641-A1 | PYRAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-7544675-B2 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2009-06-09 | — | — | US | disclosed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | PDE7A, CHRM3, PDE4B | PDE10A 27/4885NR1I2 1293/4885CYP3A4 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.